CN101195613B - 一类具有取代四元环结构的化合物及其医学用途 - Google Patents

一类具有取代四元环结构的化合物及其医学用途 Download PDF

Info

Publication number
CN101195613B
CN101195613B CN2006101191092A CN200610119109A CN101195613B CN 101195613 B CN101195613 B CN 101195613B CN 2006101191092 A CN2006101191092 A CN 2006101191092A CN 200610119109 A CN200610119109 A CN 200610119109A CN 101195613 B CN101195613 B CN 101195613B
Authority
CN
China
Prior art keywords
group
substituted
contain
interior
halogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006101191092A
Other languages
English (en)
Chinese (zh)
Other versions
CN101195613A (zh
Inventor
王明伟
陈德溯
李娜
刘青
廖嘉渝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chinese Academy of Sciences CAS
Shanghai Institute of Materia Medica of CAS
Original Assignee
Shanghai Institute of Materia Medica of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica of CAS filed Critical Shanghai Institute of Materia Medica of CAS
Priority to CN2006101191092A priority Critical patent/CN101195613B/zh
Priority to PCT/CN2007/002959 priority patent/WO2008067711A1/fr
Publication of CN101195613A publication Critical patent/CN101195613A/zh
Application granted granted Critical
Publication of CN101195613B publication Critical patent/CN101195613B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2006101191092A 2006-12-05 2006-12-05 一类具有取代四元环结构的化合物及其医学用途 Expired - Fee Related CN101195613B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN2006101191092A CN101195613B (zh) 2006-12-05 2006-12-05 一类具有取代四元环结构的化合物及其医学用途
PCT/CN2007/002959 WO2008067711A1 (fr) 2006-12-05 2007-10-16 Composés à structure du cycle à 4 éléments substitués et leurs utilisations en tant que médicament

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2006101191092A CN101195613B (zh) 2006-12-05 2006-12-05 一类具有取代四元环结构的化合物及其医学用途

Publications (2)

Publication Number Publication Date
CN101195613A CN101195613A (zh) 2008-06-11
CN101195613B true CN101195613B (zh) 2012-08-08

Family

ID=39491650

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006101191092A Expired - Fee Related CN101195613B (zh) 2006-12-05 2006-12-05 一类具有取代四元环结构的化合物及其医学用途

Country Status (2)

Country Link
CN (1) CN101195613B (fr)
WO (1) WO2008067711A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101195612B (zh) * 2006-12-05 2012-08-08 中国科学院上海药物研究所 一类具有取代环丁烷结构的化合物、及其制备方法和医学用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1626521A (zh) * 2003-12-12 2005-06-15 中国科学院上海药物研究所 一类胰高血糖样肽－1 受体激动剂及其制备方法和用途
CN101195612A (zh) * 2006-12-05 2008-06-11 中国科学院上海药物研究所 一类具有取代环丁烷结构的化合物、及其制备方法和医学用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1884278A (zh) * 2005-06-24 2006-12-27 中国科学院上海药物研究所 一类胰高血糖样肽－1受体调节剂、制备方法和用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1626521A (zh) * 2003-12-12 2005-06-15 中国科学院上海药物研究所 一类胰高血糖样肽－1 受体激动剂及其制备方法和用途
CN101195612A (zh) * 2006-12-05 2008-06-11 中国科学院上海药物研究所 一类具有取代环丁烷结构的化合物、及其制备方法和医学用途

Also Published As

Publication number Publication date
WO2008067711A1 (fr) 2008-06-12
CN101195613A (zh) 2008-06-11

Similar Documents

Publication Publication Date Title
CN101274918A (zh) 一类取代五元杂环化合物,其制备方法和医学用途
CN101565408A (zh) 一类受体信号转导增效剂,其制备方法和用途
CN100562514C (zh) 一类取代丙酰胺衍生物、其制备方法和用途
AU2006287562B2 (en) Stabilized GLP-1 analogs
CN101505594A (zh) 代谢紊乱的组合治疗
KR100928475B1 (ko) 치환된 환형 화합물, 그의 제조 방법, 및 그의 의약적 용도
CN103987408A (zh) 通过药理学靶向Kv1.3钾通道治疗肥胖和肥胖相关病症
CN100453533C (zh) 一类胰高血糖样肽－1受体激动剂及其制备方法和用途
CN101195613B (zh) 一类具有取代四元环结构的化合物及其医学用途
CN101195612B (zh) 一类具有取代环丁烷结构的化合物、及其制备方法和医学用途
CN101195584A (zh) 一类具有取代环丙烷结构的化合物、制备方法及其医学用途
CN101195586A (zh) 一类具有取代环戊烷结构的化合物、制备方法及其医学用途
CN106749228A (zh) 一种小檗碱药物及其制备方法与应用
CN101195585A (zh) 一类具有取代环己烷结构的化合物、及其制备方法和医学用途
CN101274927B (zh) 一类四元环状化合物的光化学反应制备方法及其用途
CN1896069B (zh) 一类取代噻唑-4酮化合物、制备方法和用途
PATEL et al. Synthesis, Characterization and Biological Evaluation of Thiazolidine-2, 4-dione Derivative.
Islam A review on synthesis, characterization, and pharmacological evaluation of second-line antidiabetic drugs
Berger et al. Long-Circulating Vasoactive 1, 18-Octadecanedioic Acid–Terlipressin Conjugate
JP2008195625A (ja) Ｇ蛋白質共役型レセプター抑制剤および医薬

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120808

Termination date: 20151205

EXPY Termination of patent right or utility model